释放向癌症中的血管新素II型1受体的潜力
David R Butcher1, Christopher N Parris1, Scott J Crichton2
1Anglia Ruskin University, Cambridge, UK.
Oncogene
|December 17, 2025
概括
ангиотензин II 1 型受体 (AT1R) 阻断剂通过抑制瘤生长和转移,在癌症治疗中表现有前途. 临床转换是不一致的,需要生物标志物驱动的试验有效的AT1R向瘤学.
科学领域:
- 在瘤学瘤学.
- 心血管药理学心血管药理学
- 癌症生物学 癌症生物学
背景情况:
- 氨酸- ангиотензин系统调节血压,并通过 angiotensin II 1 型受体 (AT1R) 影响癌症的进展.
- 增加AT1R表达与各种癌症的不良预后和治疗耐药性相关.
- AT1R的激活促进了瘤的扩散,血管新生和转移.
研究的目的:
- 审查AT1R在癌症中的作用.
- 总结前临床和临床研究在瘤学中准宁-血管素系统 (RAS).
- 提出优化AT1R向癌症治疗的战略.
主要方法:
- 通过血管激素受体抑制剂 (ARBs) 抑制AT1R的临床前研究的综述.
- 对ARB对瘤微环境 (TME) 和治疗功效的影响的分析.
- 检查临床试验数据和对癌症ARB的回顾性人口研究.
主要成果:
- 临床前数据表明ARB抑制瘤生长,诱导亡,减少血管生成,并抑制转移.
- ARBs调节TME,增强抗瘤免疫力和其他癌症治疗的有效性.
- 由于试验设计和患者异质性,ARB在瘤学中的临床转化是不一致的.
结论:
- 在瘤学中,AT1R是重要的点,对ARB疗效有强烈的临床前支持.
- 克服临床翻译挑战需要创新的传递系统和先进的治疗方式.
- 生物标志物驱动的临床试验对于定义AT1R的作用和确定其在联合癌症治疗中的实用性至关重要.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K